Catalog No.S1332 Synonyms: RO 15-1788
Molecular Weight(MW): 303.29
Flumazenil is a competitive GABAA receptor antagonist, used in the treatment of benzodiazepine overdoses.
Purity & Quality Control
Choose Selective GABA Receptor Inhibitors
|Description||Flumazenil is a competitive GABAA receptor antagonist, used in the treatment of benzodiazepine overdoses.|
|In vivo||Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists. Flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected.  Flumazenil (1 mg/kg) induces a strong anxiolytic effect in BALB/c mice tested in the elevated plus maze and light/dark test.  Flumazenil (10 mg/kg) effectively prevents the reduction produced by allopregnanolone in rats.  Flumazenil (5-20 mg/kg) antagonizes the anticonvulsant and adverse effects of diazepam but not GYKI 52466 in mice. Flumazenil slightly reduces the anticonvulsant activity of NBQX in the MES model but not in the PTZ test.  Flumazenil (3.0 mg/kg) blocks the changes withdrawal from chronic ethanol treatment, which leads to a decrease in open arm time and percent open arm entries. |
-  Hoffman EJ, et al. Clin Pharm, 1993, 12(9), 641-656.
-  Belzung C, et al. Psychopharmacology (Berl), 2000, 148(1), 24-32.
-  Fern醤dez-Guasti A, et al. Eur J Pharmacol, 1995, 281(1), 113-115.
|In vitro||DMSO||5 mg/mL (16.48 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02899156||Recruiting||Delirium||University of California, Davis||March 2016||Phase 4|
|NCT02690389||Completed||Acupuncture|General Anaesthesia|Sedation||Dr. Yin Liu|Sichuan Cancer Hospital and Research Institute||January 2015||--|
|NCT02048969||Recruiting||Hepatic Encephalopathy|Liver Cirrhosis||Yale University||June 2014||Phase 1|Phase 2|
|NCT01651520||Recruiting||Multiple Sclerosis||Assistance Publique - Hôpitaux de Paris||March 2013||--|
|NCT01904487||Terminated||Alcoholism||Rajesh Narendran|University of Pittsburgh||April 2011||Phase 1|
|NCT02157428||Completed||Adverse Effect of Other General Anesthetics||University of Sao Paulo||January 2011||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.